Exagen (XGN) Gains 6.07% on June 23

Equities Staff  |

Today Exagen Inc (NASDAQ: XGN) is trading 6.07% higher.

The latest price, as of 12:12:26 est, was $5.94. Exagen has risen $0.34 so far today.

12,027 shares exchanged hands.

As of the previous close, Exagen has a YTD change of 51.85%. The company is set to release earnings on 2022-08-08.

For technical charts, analysis, and more on Exagen visit the company profile.

About Exagen Inc

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on the proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

To get more information on Exagen Inc and to follow the company's latest updates, you can visit the company's profile page here: Exagen Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content